[The role of drug Cytoflavin in the correction of dysautonomia in patients with post-COVID syndrome].

Objective: To evaluate the autonomic dysfunction of cardiovascular system (CVS) in patients with post-COVID syndrome with the help of active orthotest and heart rate variability methods.

Material And Methods: 70 patients with PCOS were examined, who were divided into 2 groups. Group 1 patients received standard therapy and Cytoflavin for 35 days, Group 2 patients received only standard therapy. Patients were examined by a neurologist in dynamics, the severity of asthenic syndrome was assessed on the MFI-20 scale, HRV and orthostatic test parameters.

Results: When assessing HRV, an increase in the activity of humoral and nervous levels of CVS regulation was observed, which decreased against the background of cytoflavin therapy. Prior to the start of treatment, the activity of the parasympathetic department prevailed in patients, despite a decrease in its reactivity. All patients had a change in parasympathetic regulation, and therefore they were divided into subgroups with excessive and insufficient parasympathetic activity. Against the background of therapy, the elimination of differences between the groups with normalization of the main HRV indicators was observed. The severity of asthenia decreased after the course of treatment (values on the MFI-20 scale, =0.0498).

Conclusion: In patients with PKS, signs of dysautonomia were revealed, the probable cause of which may be autonomic neuropathy with a predominant lesion of the parasympathetic link. The use of Cytoflavin can have a significant positive effect in the complex treatment of such patients.